1. Trang chủ
  2. » Luận Văn - Báo Cáo

Cập nhật điều trị Rối loạn Lipid máu năm 2016

44 530 0

Đang tải... (xem toàn văn)

Tài liệu hạn chế xem trước, để xem đầy đủ mời bạn chọn Tải xuống

THÔNG TIN TÀI LIỆU

Thông tin cơ bản

Định dạng
Số trang 44
Dung lượng 4,5 MB

Nội dung

Dyslipidemia Management in 2016 Michael Heffernan MD PhD FRCPC FACC Faculty/Presenter  Disclosure   •  Faculty:  Dr  Michael  Heffernan   •  Title  of  Talk:  2016  Dyslipidemia  Update   •  Relationships  with  commercial  interests:   •  Grants/Research  Support:  Bayer,  Boehringer  Ingelheim,   Esai,  AstraZeneca   •  Speakers  Bureau/Honoraria:  AstraZeneca,  Bayer,   Boehringer  Ingelheim,  Bristol  Myers  Squibb,  Pfizer,  Amgen,   Servier,  Sanofi   •  Consulting  Fees:  Bayer,  AstraZeneca,  Boehringer   Ingelheim,  Amgen,  Sanofi   •  Other:  None   Objectives   At  the  end  of  this  presentation,  the  participant  will  be  able   to:     Identify patients not at LDL-C goal despite current treatment and discuss why they would benefit from further LDL-C reduction   Appraise clinical data and new treatment strategies to lower LDL-C in the high risk patient   Discuss clinical management of the high risk patient not at goal and implementation of new treatment strategies The Case: John   56y  male     HTN,  dyslipidemia     Previous  MI  and  angioplasty   at  age  48y     Family  history  of  premature   CAD     Non-­‐smoker     Exercises  100  min/week     ALended  cardiac  rehab  and   adheres  to  dietary  guidelines   The Case   Medica'ons   −  ASA  81  mg  once  daily     −  AtorvastaOn  20  mg   −  Bisoprolol  5  mg  once  daily   −  Ramipril  10  mg  once  daily     Lipid  Profile   −  TC:  5.9  mmol/L   −  TG:1.4  mmol/L     −  HDL-­‐C:  1.4  mmol/L   −  LDL-­‐C:  3.6  mmol/L  (current)   −  non-­‐HDL-­‐C:  4.3  mmol/L     −  He  has  tried  rosuvastaOn  but  was  unable  to  tolerate  it  (mylagias)   −  He  was  on  40  mg  of  atorvastaOn  however  this  also  provoked  myalgias   −  He  can  tolerate  20  mg  of  atorvastaOn   What is John’s Target and Why Do We Want to Get Him There ? The Cholesterol Hypothesis Originated with Observational Studies Epidemiologic Data – Serum Cholesterol Levels and CHD MRFIT trial: age-adjusted CHD death rate and serum cholesterol in 361,662 US men (aged 35–57 years) Each 1% Increase in Total Cholesterol Level is associated with a 2% Increase in CHD Risk Martin MJ, et al Lancet 1986;2:933–936 Clinical Trials Validated The LDL Hypothesis 30 These trials have demonstrated that LDL-C lowering is associated with greater reduction of CHD events CHD Event Rate,% 25 Secondary Prevention 4S-P 20 4S-T 15 1O DIABETES PREVENTION Care-P Care-T 10 HPS-T PROS-T TNT-80 TNT-10 Ascot-T JUP-T 1.3 1.8 Lipid-T HPS-P PROS-P WPS-P AFCAPS-P CARDS-T Lipid-P 2.5 Primary Prevention JUP-P AFCAPS-T WPS-T Ascot-P 3.0 3.5 4.0 LDL-C mmol/L 4.5 5.0 5.4 @>4'(.:(24'$*2(&:%(8:$*2/&'/.:.[$Y@**Z$@4''&M42&O48T$V&8G(:T$PIHI\X]"SH"]ICH"5 years Additional populations ODYSSEY CHOICE II Patients with hypercholesterolemia on non-statin LMT or diet N=200; months ODYSSEY OPTIONS I Patients not at goal with moderate dose atorvastatin N=355; months ODYSSEY OPTIONS II Patients not at goal with moderate dose rosuvastatin N=305; months Interesting Concept, But Will It Help John ? OSLER: Evolocumab Plus Standard of Care Achieved a 61% Reduction in LDL-C over Standard of Care at 12 Weeks 3.6 3.1 mmol/L 3.1 2.6 61% reduction (95%CI 59-63%), P,$+48C?&:&'$67,$=&:&'$&8-$848C?&:&'$/.G>(%/G$.:24D(,$p8.:&M'($ &89/8&$2(i5/2/89$>4.0/:&'/d&O48T$VV*,$'/0/-C'4K(2/89$:>(2&0#$ † q$!P$K((D.$?42$&''$0&O(8:.$G48O85/89$:2(&:%(8:,$/8G'T$"I]$0&O(8:.$K>4$G4%0'(:(-$o](&2:$-/.(&.(T$^A6AT$HU]!\PXHY;ZSX"IcX($V/0/-$R(.(&2G>$@'/8/G.$@4248&2#$12/%&2#$12(3(8O48$*2/&'$2(.5':.T$^A6A$ HU[...]... NOT at LDL-C target1* ($ 2 mmol/L) !! 88% of patients received a ‘potent’ statin with suboptimal dose !! 14% of patients received additional lipid- lowering agent 43% Canadian patients with diabetes are NOT at LDL-C target2† ($ 2 mmol/L) !! 82% of patients were on a lipid- lowering agent g)/9>$2/.D$k$ g)/9>$2/.D$k$,./.#+/0!+/-(/0!)12(+2(3!4(/145(/+%!+/-(/1+%!)12(+2(3!,(/(6/.7+2,8%+/!)12(+2(3!)1+6(-(2!9(%%1-82!./!:/+91#$5+9!;!2,./(!?@ 5.0 mmol/L #!Familial hypercholesterolemia !50% reduction in LDL-C Alternate Target #!LDL-C > 3.5 mmol/L... from Jones P, et al for the CURVES Investigators Am J Cardiol 1998;81:582-587 Add-On Therapy has had Moderate Benefit in Further Lowering LDL-C Add-On Therapy$ LDL-C Lowering+ Niacin4-6$ 20% + Other Lipid Effects+ Outcome Data (Add-on to statin)+ " HDL by 30% # TG by 40%$ No benefit as addon to statin7,8$ " HDL-C (10-50%) # TG (20-50%) No benefit as add-on to statin$ Fibrates9,10$ 5 – 20%+ Bile Acid... (%) 50 40 Ezetimibe Fibrate Bile acid resin 30 Niacin Diet/unsat Fatty acid 20 Ileal bypass CTTC trials (statin) 10 IMPROVE-IT 0 0.3 0.5 0.8 1.0 1.3 1.5 Reduction in LDL-C (mmol/L) 1.8 2.1 Non-statin lipid- lowering studies suggest coronary event reduction is due to LDL-C reduction, independent of method @>4'(.:(24'$*2(&:%(8:$*2/&'/.:.[$@4''&M42&O48T$V&8G(:T$PII!\X""SHP"]CHP]($@4248&2#$B259$124b(G:$R(.(&2G>$W2450T$^A6AT$HU]!\PXHSX"IcX

Ngày đăng: 30/08/2016, 20:04

TỪ KHÓA LIÊN QUAN

w